Abiopharma

🔍 Walker Robert Edward (Executive)

Company: NOVAVAX INC (NVAX)

Report Date: 2026-04-14

Detailed Transactions and Holdings:

• Acquired 99,500 shares of Stock Option (Right to Buy) at $8.46 per share (Derivative)
  Date: 2026-04-14 | Code: A | Expires: 2036-04-14 | equity_swap_involved: 0 | shares_owned_after: 99,500.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 66,000 shares of Restricted Stock Units (Derivative)
  Date: 2026-04-14 | Code: A | equity_swap_involved: 0 | shares_owned_after: 6,600.00 | transaction_form_type: 4 | Footnotes: F2, F3, F3

Footnotes:

• F1: Twenty-five percent (25%) of the shares subject to this option granted under the Novavax, Inc. (the "Company") Amended and Restated 2015 Stock Incentive Plan, as amended, vest on the first anniversary of the grant date, and the remaining seventy-five percent (75%) of the shares vest in equal monthly installments over the following three (3) years, in each case subject to continued employment with the Company through such vesting date.
• F2: Each RSU represents a contingent right to receive one share of the "Company" common stock.
• F3: The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the April 14, 2026 grant date, in each case subject to continued employment with the Company through such vesting date.